[Hepatitis C treatment in consideration of the carcinogenic risk and drug-resistant mutations]

Nihon Rinsho. 2015 Dec:73 Suppl 9:165-70.
[Article in Japanese]
No abstract available

MeSH terms

  • Antiviral Agents / therapeutic use
  • Drug Resistance, Viral*
  • Hepacivirus / genetics*
  • Hepatitis C / complications*
  • Hepatitis C / drug therapy
  • Humans
  • Liver Neoplasms / etiology*
  • Mutation*
  • Risk Factors

Substances

  • Antiviral Agents